Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

    October 2019 in “ JNCI Cancer Spectrum ”
    Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung-Hun Lee, Louis Fehrenbacher, Lida A. Mina, Sami Diab, Natasha Woodward, Rinat Yerushalmi, Annabel Goodwin, Joanne L. Blum, Miguel Martín, Ruben G.W. Quek, Iulia Cristina Tudor, Helen Bhattacharyya, Eric Gauthier, Jennifer K. Litton, W. Eiermann
    TLDR Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
    The EMBRACA study was a phase III trial that compared talazoparib, a PARP inhibitor, with physician's choice chemotherapy (PCT) in 431 patients with advanced breast cancer and BRCA1/2 mutations. Talazoparib significantly improved progression-free survival and objective response rates across all patient subgroups compared to PCT, with hazard ratios of 0.47 for HR+/HER2− and 0.60 for TNBC subgroups. It also showed better patient-reported outcomes and delayed deterioration. Common adverse events included anemia and fatigue for talazoparib, and neutropenia and fatigue for PCT. Alopecia was observed in 2.4% of patients as grade II and 22.7% as grade I with talazoparib. Overall, talazoparib demonstrated clinically significant superiority in outcomes compared to PCT for patients with gBRCA-mutated advanced breast cancer.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Alopecia Areata Question

      in Treatment  2 upvotes 4 years ago
      A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

      community mbp alopecia areata or vitamin deficiency

      in Chat 1 year ago
      A 19-year-old male has been using topical finasteride and minoxidil for 8 months with no progress and is considering seeking a second opinion due to potential misdiagnosis. The discussion revolves around whether the hair loss is due to male pattern baldness, alopecia areata, or a vitamin deficiency.

      community Androgenic alopecia exclusively on the vertex of the scalp

      in Chat  6 upvotes 1 year ago
      A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.

      community Fibrosing alopecia in a pattern distribution

      in Research/Science  14 upvotes 1 year ago
      A user has been experiencing hair loss for 4 years, with treatments like minoxidil, finasteride, and various supplements proving ineffective. They were diagnosed with fibrosing alopecia in a pattern distribution, a condition that may require a combination of anti-inflammatory and hair growth treatments.

    Similar Research

    5 / 1000+ results